Trial Profile

Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Carboplatin; Etoposide phosphate; Ifosfamide
Indications Cancer metastases; CNS cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Hepatic tumours; Liver cancer; Lymphoma; Neuroblastoma; Osteosarcoma; Renal cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Testicular cancer
Focus Adverse reactions

Most Recent Events

11 Jul 2023 Status changed from active, no longer recruiting to discontinued.
03 Mar 2023 Planned End Date changed from 31 Dec 2021 to 30 Jun 2023.
03 Mar 2023 Status changed from discontinued to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com